Abstract
Hypertrophic cardiomyopathy (HCM) results from gene mutations affecting cardiac sarcomeres and is inherited in an autosomal dominant manner. With a prevalence of 1:200-1:500 in the general population, HCM is characterised by a hypertrophied and non-dilated left ventricle with predominant involvement of the interventricular septum. The myocardium's structural and intracellular factors, combined with triggers such as physical exertion, autonomic dysfunction, and ischemia, can lead to reentry events, and atrial and ventricular arrhythmias, including atrial fibrillation (AF) which is common among HCM patients. To manage the increased risk of mortality arising from congestive heart failure and thromboembolism, in patients with AF long-term anticoagulation and antiarrhythmic drugs are employed. HCM patients may also encounter supraventricular and ventricular arrhythmias, such as nonsustained ventricular tachycardia and ventricular premature beats, which can potentially lead to sudden cardiac death and necessitate treatment with implanted defibrillators. Physicians must comprehensively analyse clinical, anatomical, hemodynamic, rhythmic, functional, and genetic characteristics to identify HCM patients at high risk of sudden death. This article aims to discuss the pathophysiology of arrhythmia in HCM and clinical recommendations for various ventricular and atrial fibrillation including catheter ablation and implantable cardioverter-defibrillator (ICD).
Graphical Abstract
[1]
Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2022; 79(4): 372-89.
[http://dx.doi.org/10.1016/j.jacc.2021.12.002] [PMID: 35086660]
[http://dx.doi.org/10.1016/j.jacc.2021.12.002] [PMID: 35086660]
[2]
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy. Circ Res 2017; 121(7): 749-70.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.311059] [PMID: 28912181]
[http://dx.doi.org/10.1161/CIRCRESAHA.117.311059] [PMID: 28912181]
[3]
Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: Prevalence, clinical impact, and management. Heart Fail Rev 2019; 24(2): 189-97.
[http://dx.doi.org/10.1007/s10741-018-9752-6] [PMID: 30456592]
[http://dx.doi.org/10.1007/s10741-018-9752-6] [PMID: 30456592]
[4]
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013; 381(9862): 242-55.
[http://dx.doi.org/10.1016/S0140-6736(12)60397-3] [PMID: 22874472]
[http://dx.doi.org/10.1016/S0140-6736(12)60397-3] [PMID: 22874472]
[5]
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379(7): 655-68.
[http://dx.doi.org/10.1056/NEJMra1710575] [PMID: 30110588]
[http://dx.doi.org/10.1056/NEJMra1710575] [PMID: 30110588]
[6]
Ntusi NAB, Sliwa K. Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy. J Am Coll Cardiol 2021; 78(25): 2573-9.
[http://dx.doi.org/10.1016/j.jacc.2021.10.020] [PMID: 34887143]
[http://dx.doi.org/10.1016/j.jacc.2021.10.020] [PMID: 34887143]
[7]
Gartzonikas IK, Naka KK, Anastasakis A. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy. Hellenic J Cardiol 2022; (Nov): 70.
[PMID: 36403865]
[PMID: 36403865]
[8]
Bahrudin U, Morikawa K, Takeuchi A, et al. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol 2011; 413(4): 857-78.
[http://dx.doi.org/10.1016/j.jmb.2011.09.006] [PMID: 21939669]
[http://dx.doi.org/10.1016/j.jmb.2011.09.006] [PMID: 21939669]
[9]
Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000; 31(8): 988-98.
[http://dx.doi.org/10.1053/hupa.2000.16659] [PMID: 10987261]
[http://dx.doi.org/10.1053/hupa.2000.16659] [PMID: 10987261]
[10]
Kibos AS, Knight BP, Vidal Essebag , Fishberger SB, Slevin M. Țintoiu IC cardiac arrhythmias from basic mechanism to state-of-the-art management. London: Springer 2014.
[11]
Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. Heart 2014; 100(6): 465-72.
[http://dx.doi.org/10.1136/heartjnl-2013-304276] [PMID: 24014282]
[http://dx.doi.org/10.1136/heartjnl-2013-304276] [PMID: 24014282]
[12]
Kuck KH. Arrhythmias in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1997; 20(10): 2706-13.
[http://dx.doi.org/10.1111/j.1540-8159.1997.tb06120.x] [PMID: 9358518]
[http://dx.doi.org/10.1111/j.1540-8159.1997.tb06120.x] [PMID: 9358518]
[13]
Kumar KR, Mandleywala SN, Link MS. Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy. Card Electrophysiol Clin 2015; 7(2): 173-86.
[http://dx.doi.org/10.1016/j.ccep.2015.03.002] [PMID: 26002384]
[http://dx.doi.org/10.1016/j.ccep.2015.03.002] [PMID: 26002384]
[14]
Moore B, Semsarian C, Chan KH, Sy RW. Sudden cardiac death and ventricular arrhythmias in hypertrophic cardiomyopathy. Heart Lung Circ 2019; 28(1): 146-54.
[http://dx.doi.org/10.1016/j.hlc.2018.07.019] [PMID: 30392982]
[http://dx.doi.org/10.1016/j.hlc.2018.07.019] [PMID: 30392982]
[15]
Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35(1): 36-44.
[http://dx.doi.org/10.1016/S0735-1097(99)00492-1] [PMID: 10636256]
[http://dx.doi.org/10.1016/S0735-1097(99)00492-1] [PMID: 10636256]
[16]
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2011; 124(24): 2761-96.
[http://dx.doi.org/10.1161/CIR.0b013e318223e230] [PMID: 22068435]
[http://dx.doi.org/10.1161/CIR.0b013e318223e230] [PMID: 22068435]
[17]
Ommen SR, Mital S, Burke MA, et al. AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation 2020; 142(25)
[18]
Hermida U, Stojanovski D, Raman B, et al. Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: Beyond basal septal hypertrophy. Eur Heart J Cardiovasc Imaging 2023; 24(6): 807-18.
[http://dx.doi.org/10.1093/ehjci/jeac233] [PMID: 36441173]
[http://dx.doi.org/10.1093/ehjci/jeac233] [PMID: 36441173]
[19]
Shen H, Dong SY, Ren MS, Wang R. Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside. Front Cardiovasc Med 2022; 9: 949294.
[http://dx.doi.org/10.3389/fcvm.2022.949294] [PMID: 36061538]
[http://dx.doi.org/10.3389/fcvm.2022.949294] [PMID: 36061538]
[20]
Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: Theory and practice. Heart 2007; 94(10): 1269-75.
[http://dx.doi.org/10.1136/hrt.2008.154385] [PMID: 18653582]
[http://dx.doi.org/10.1136/hrt.2008.154385] [PMID: 18653582]
[21]
Michels M. Appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: What happens on Sunday afternoons in May? Europace 2012; 14(5): 621-2.
[http://dx.doi.org/10.1093/europace/eus018] [PMID: 22345376]
[http://dx.doi.org/10.1093/europace/eus018] [PMID: 22345376]
[22]
Bockstall KE, Link MS. A primer on arrhythmias in patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2012; 14(5): 552-62.
[http://dx.doi.org/10.1007/s11886-012-0297-3] [PMID: 22825919]
[http://dx.doi.org/10.1007/s11886-012-0297-3] [PMID: 22825919]
[23]
Baudenbacher F, Schober T, Pinto JR, et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 2008; 118(12): 3893-903.
[http://dx.doi.org/10.1172/JCI36642] [PMID: 19033660]
[http://dx.doi.org/10.1172/JCI36642] [PMID: 19033660]
[24]
Schober T, Huke S, Venkataraman R, et al. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res 2012; 111(2): 170-9.
[http://dx.doi.org/10.1161/CIRCRESAHA.112.270041] [PMID: 22647877]
[http://dx.doi.org/10.1161/CIRCRESAHA.112.270041] [PMID: 22647877]
[25]
Coppini R, Ferrantini C, Yao L, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2013; 127(5): 575-84.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.134932] [PMID: 23271797]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.134932] [PMID: 23271797]
[26]
Yang KC, Jay PY, McMullen JR, Nerbonne JM. Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure. Cardiovasc Res 2012; 93(2): 252-62.
[http://dx.doi.org/10.1093/cvr/cvr283] [PMID: 22038742]
[http://dx.doi.org/10.1093/cvr/cvr283] [PMID: 22038742]
[27]
Frey N, Luedde M, Katus HA. Mechanisms of disease: Hypertrophic cardiomyopathy. Nat Rev Cardiol 2012; 9(2): 91-100.
[http://dx.doi.org/10.1038/nrcardio.2011.159] [PMID: 22027658]
[http://dx.doi.org/10.1038/nrcardio.2011.159] [PMID: 22027658]
[28]
Ali A, Pecha S, Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: diagnosis and considerations for management. J Atr Fibrillation 2018; 10(5): 1556.
[http://dx.doi.org/10.4022/jafib.1556] [PMID: 29988228]
[http://dx.doi.org/10.4022/jafib.1556] [PMID: 29988228]
[29]
Dragasis S, Vlachos K, Kariki O, et al. Atrial fibrillation in hypertrophic cardiomyopathy - A contemporary mini-review. Hellenic journal of cardiology: HJC = Hellenike kardiologike epitheorese 2022; 67: 66-72.
[30]
Prinz C, Vanbuuren F, Bogunovic N, Bitter T, Faber L, Horstkotte D. In patients with hypertrophic cardiomyopathy myocardial fi brosis is associated with both left ventricular and left atrial dysfunction. Acta Cardiol 2012; 67(2): 187-93.
[http://dx.doi.org/10.1080/AC.67.2.2154209] [PMID: 22641976]
[http://dx.doi.org/10.1080/AC.67.2.2154209] [PMID: 22641976]
[31]
Papavassiliu T, Germans T, Flüchter S, et al. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson 2009; 11(1): 34.
[http://dx.doi.org/10.1186/1532-429X-11-34] [PMID: 19740409]
[http://dx.doi.org/10.1186/1532-429X-11-34] [PMID: 19740409]
[32]
Rahmani G, Kraushaar G, Dehghani P. Diagnosing burned-out hypertrophic cardiomyopathy: Daughter’s phenotype solidifies father’s diagnosis. J Cardiol Cases 2015; 11(3): 78-80.
[http://dx.doi.org/10.1016/j.jccase.2014.10.010] [PMID: 30546535]
[http://dx.doi.org/10.1016/j.jccase.2014.10.010] [PMID: 30546535]
[33]
Mielczarek S, Syska P, Lewandowski M, Kowalik I, Pytkowski M, Szwed H. Long-term mortality and risk factor analysis in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillators. Polish Archives of Internal Medicine 2022; 132(2): 16206.
[http://dx.doi.org/10.20452/pamw.16206]
[http://dx.doi.org/10.20452/pamw.16206]
[34]
Kubo T, Kitaoka H, Okawa M, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ J 2009; 73(9): 1599-605.
[http://dx.doi.org/10.1253/circj.CJ-09-0140] [PMID: 19590139]
[http://dx.doi.org/10.1253/circj.CJ-09-0140] [PMID: 19590139]
[35]
Guttmann OP, Pavlou M, O’Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart 2017; 103(9): 672-8.
[http://dx.doi.org/10.1136/heartjnl-2016-309672] [PMID: 27794017]
[http://dx.doi.org/10.1136/heartjnl-2016-309672] [PMID: 27794017]
[36]
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104(21): 2517-24.
[http://dx.doi.org/10.1161/hc4601.097997] [PMID: 11714644]
[http://dx.doi.org/10.1161/hc4601.097997] [PMID: 11714644]
[37]
Segev A, Wasserstrum Y, Arad M, et al. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome. Heart Rhythm 2023; 20(10): 1385-92.
[http://dx.doi.org/10.1016/j.hrthm.2023.06.015] [PMID: 37385464]
[http://dx.doi.org/10.1016/j.hrthm.2023.06.015] [PMID: 37385464]
[38]
Rowin EJ, Maron BJ, Maron MS. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging. JACC Cardiovasc Imaging 2020; 13(9): 2002-16.
[http://dx.doi.org/10.1016/j.jcmg.2019.09.020] [PMID: 31864978]
[http://dx.doi.org/10.1016/j.jcmg.2019.09.020] [PMID: 31864978]
[39]
Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44(11): 2125-32.
[http://dx.doi.org/10.1016/j.jacc.2004.08.052] [PMID: 15582308]
[http://dx.doi.org/10.1016/j.jacc.2004.08.052] [PMID: 15582308]
[40]
Norrish G, Jager J, Field E, et al. Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives. Circulation 2019; 140(3): 184-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038846] [PMID: 31006259]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038846] [PMID: 31006259]
[41]
Maron BJ, McKenna WJ, Danielson GK, et al. American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42(9): 1687-713.
[http://dx.doi.org/10.1016/S0735-1097(03)00941-0] [PMID: 14607462]
[http://dx.doi.org/10.1016/S0735-1097(03)00941-0] [PMID: 14607462]
[42]
Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2005; 92(6): 785-91.
[http://dx.doi.org/10.1136/hrt.2005.068577] [PMID: 16216855]
[http://dx.doi.org/10.1136/hrt.2005.068577] [PMID: 16216855]
[43]
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2733-79.
[http://dx.doi.org/10.1093/eurheartj/ehu284] [PMID: 25173338]
[http://dx.doi.org/10.1093/eurheartj/ehu284] [PMID: 25173338]
[44]
Makavos G, Κairis C, Tselegkidi ME, et al. Hypertrophic cardiomyopathy: An updated review on diagnosis, prognosis, and treatment. Heart Fail Rev 2019; 24(4): 439-59.
[http://dx.doi.org/10.1007/s10741-019-09775-4] [PMID: 30852773]
[http://dx.doi.org/10.1007/s10741-019-09775-4] [PMID: 30852773]
[45]
Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130(6): 484-95.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007094] [PMID: 25092278]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007094] [PMID: 25092278]
[46]
Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118(15): 1541-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.781401] [PMID: 18809796]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.781401] [PMID: 18809796]
[47]
Rowin EJ, Maron BJ, Chokshi A, Maron MS. Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. Pacing Clin Electrophysiol 2018; 41(8): 1031-3.
[http://dx.doi.org/10.1111/pace.13413] [PMID: 29893504]
[http://dx.doi.org/10.1111/pace.13413] [PMID: 29893504]
[48]
Roberts BD, Hood R, Saba MM, Dickfeld TM, Saliaris AP, Shorofsky SR. Defibrillation threshold testing in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2010; 33(11): 1342-6.
[http://dx.doi.org/10.1111/j.1540-8159.2010.02843.x] [PMID: 20663074]
[http://dx.doi.org/10.1111/j.1540-8159.2010.02843.x] [PMID: 20663074]
[49]
Nagai T, Kurita T, Satomi K, et al. QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy. Circ J 2009; 73(6): 1028-32.
[http://dx.doi.org/10.1253/circj.CJ-08-0744] [PMID: 19359812]
[http://dx.doi.org/10.1253/circj.CJ-08-0744] [PMID: 19359812]
[50]
Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 2006; 48(5): e247-346.
[http://dx.doi.org/10.1016/j.jacc.2006.07.010] [PMID: 16949478]
[http://dx.doi.org/10.1016/j.jacc.2006.07.010] [PMID: 16949478]
[51]
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363(1): 36-44.
[http://dx.doi.org/10.1056/NEJMoa0909545] [PMID: 20463331]
[http://dx.doi.org/10.1056/NEJMoa0909545] [PMID: 20463331]
[52]
Gimeno JR, Tomé-Esteban M, Lofiego C, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30(21): 2599-605.
[http://dx.doi.org/10.1093/eurheartj/ehp327] [PMID: 19689975]
[http://dx.doi.org/10.1093/eurheartj/ehp327] [PMID: 19689975]
[53]
Nazer B, Dale Z, Carrassa G, et al. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. Heart Rhythm 2020; 17(7): 1107-14.
[http://dx.doi.org/10.1016/j.hrthm.2020.02.008] [PMID: 32084597]
[http://dx.doi.org/10.1016/j.hrthm.2020.02.008] [PMID: 32084597]
[54]
Patel N, Elzanaty A, Patel M, Elsheikh E. Efficacy and safety of direct anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A systematic review and meta-analysis. J Am Coll Cardiol 2021; 77(18): 1727.
[http://dx.doi.org/10.1016/S0735-1097(21)03083-7]
[http://dx.doi.org/10.1016/S0735-1097(21)03083-7]
[55]
Nasser MF, Gandhi S, Siegel RJ, Rader F. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: A review. Heart Rhythm 2020.
[PMID: 33022393]
[PMID: 33022393]
[56]
Lin Y, Xiong H, Su J, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. Heart Vessels 2022; 37(7): 1224-31.
[http://dx.doi.org/10.1007/s00380-022-02021-2] [PMID: 35041061]
[http://dx.doi.org/10.1007/s00380-022-02021-2] [PMID: 35041061]
[57]
Huang CY, Yang YH, Lin LY, et al. Renin–angiotensin–aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. Heart 2018; 104(15): 1276-83.
[http://dx.doi.org/10.1136/heartjnl-2017-312573] [PMID: 29371376]
[http://dx.doi.org/10.1136/heartjnl-2017-312573] [PMID: 29371376]
[58]
Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: An individualized approach to clinical staging. Circ Heart Fail 2012; 5(4): 535-46.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.967026] [PMID: 22811549]
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.967026] [PMID: 22811549]
[59]
Torres MF, Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018; 2018(3): 32.
[http://dx.doi.org/10.21542/gcsp.2018.32] [PMID: 30393644]
[http://dx.doi.org/10.21542/gcsp.2018.32] [PMID: 30393644]
[60]
Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2012; 110(4): 568-74.
[http://dx.doi.org/10.1016/j.amjcard.2012.04.030] [PMID: 22591671]
[http://dx.doi.org/10.1016/j.amjcard.2012.04.030] [PMID: 22591671]
[61]
Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3(5): 574-9.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.922872] [PMID: 20736440]
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.922872] [PMID: 20736440]
